SVB Wealth LLC Reduces Stock Position in Gilead Sciences, Inc. $GILD

SVB Wealth LLC cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 19.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 29,779 shares of the biopharmaceutical company’s stock after selling 7,306 shares during the period. SVB Wealth LLC’s holdings in Gilead Sciences were worth $3,655,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Corundum Trust Company INC purchased a new stake in Gilead Sciences in the third quarter valued at approximately $26,000. Ares Financial Consulting LLC purchased a new position in Gilead Sciences during the 4th quarter worth approximately $28,000. Financial Consulate Inc. lifted its stake in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 109 shares during the period. North Star Investment Management Corp. boosted its holdings in shares of Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 86 shares during the last quarter. Finally, MTM Investment Management LLC boosted its holdings in shares of Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 176 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GILD has been the subject of a number of research reports. Sanford C. Bernstein restated an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a research report on Wednesday, February 11th. Cantor Fitzgerald cut their price target on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, April 10th. Bank of America set a $162.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, February 11th. Oppenheimer boosted their price objective on Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $157.15.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Truist Financial reaffirmed its buy rating on Gilead and raised its price target to $157 from $155, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Gilead reported Q1 EPS of $2.03 and revenue of $6.96 billion, both ahead of analyst expectations, supported by HIV and Trodelvy sales growth. Yahoo Finance
• Positive Sentiment: The company raised its Yeztugo 2026 sales guidance to $1 billion from $800 million, signaling stronger-than-expected launch momentum. Yahoo Finance
• Neutral Sentiment: RBC slightly reduced its price target to $122 from $123 and kept a sector perform view, suggesting a more cautious stance but no major change in thesis. Benzinga
• Negative Sentiment: Gilead cut its 2026 EPS guidance to a loss range of -$1.05 to -$0.65, a major deterioration from prior profit expectations, due to acquisition charges and financing costs. Reuters
• Negative Sentiment: Investors also appear concerned that near-term growth is being driven more by older products like Descovy and Biktarvy than by the much-anticipated Yeztugo launch, creating questions about the pace of future growth. Yahoo Finance

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $131.33 on Monday. The company has a market capitalization of $163.01 billion, a PE ratio of 17.89 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The company’s fifty day moving average price is $139.59 and its 200 day moving average price is $132.87. Gilead Sciences, Inc. has a 1 year low of $96.18 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post -0.85 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is currently 44.69%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the sale, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at approximately $81,702,353.72. This trade represents a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the sale, the insider owned 120,288 shares of the company’s stock, valued at $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 63,000 shares of company stock valued at $9,238,250. 0.30% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.